An overview of the LITESPARK-003 study of belzutifan from ESMO 2023 and the role of HIF2α inhibitors in renal cell carcinoma (RCC).
This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.
Daneshmand discusses results from the LITESPARK-003 phase 2 trial evaluating belzutifan plus cabozantinib in advanced RCC. Belzutifan is a HIF-2α inhibitor approved for Von Hippel–Lindau disease–associated RCC. The LITESPARK-003 trial had 2 cohorts; cohort 1 was first-line, and cohort 2 was subsequent line therapy.
Cohort 1 included 50 patients with favorable risk, whereas cohort 2 had 51 patients with intermediate/poor risk. At a median follow-up of 2 years in cohort 1 and 40 months in cohort 2, median overall survival was not reached in cohort 1 and was 26.7 months in cohort 2. The combination showed antitumor activity and was fairly well tolerated, with no treatment-related deaths.
Daneshmand notes that although these are exciting results, determining the optimal place for belzutifan combinations within the evolving RCC treatment landscape of multiple combinations therapies remains to be seen. Nonetheless, having additional active targeted therapy options is positive.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen